Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver

British Journal of Surgery

Volumn 90, Issue 11, 2003, Pages 1391-1397

  Rothbarth, J ^a   Pijl, M E J ^a   Vahrmeijer, A L ^a   Hartgrink, H H ^a   Tijl, F G J ^a   Kuppen, P J K ^a   Tollenaar, R A E M ^a   Van De Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MELPHALAN; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0242552650     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4308     Document Type: Article

References (35)

1. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132: 505-510.
2. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946.
3. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88: 980-985.
4. Buell JF, Rosen S, Yoshida A, Labow D, Limsrichamrern S, Cronin DC et al. Hepatic resection: effective treatment for primary and secondary tumors. Surgery 2000; 128: 686-693.
5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
6. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6: 3062-3070.
7. Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16: 1479-1489.
8. Aigner KR, Walther H, Link KH. Isolated liver perfusion with MMC/5-FU: surgical technique, pharmacokinetics, clinical results. Contr Oncol 1988; 29: 229-246.
9. Hafstrom LR, Holmberg SB, Naredi PL, Lindner PG, Bengtsson A, Tidebrant G et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994; 3: 103-108.
10. Marinelli A, de Brauw LM, Beerman H, Keizer HJ, van Bockel JH, Tjaden UR et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996; 26: 341-350.
11. Oldhafer KJ, Lang H, Frerker M, Moreno L, Chavan A, Flemming P et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery 1998; 123: 622-631.
12. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129: 176-187.
13. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000; 82: 1539-1546.
14. de Vries MR, Rinkes IH, van de Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 1998; 147: 107-119.
15. Runia RD, de Brauw LM, Kothuis BJ, Pauwels EK, van de Velde CJ. Continuous measurement of leakage during isolated liver perfusion with a radiotracer. Int J Rad Appl Instrum B 1987; 14: 113-118.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
17. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg 1982; 6: 3-9.
18. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19: 2687-2695.
19. Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder G et al. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. Cancer 2001; 92: 2746-2753.
20. O'Connell MJ, Nagorney DM, Bernath AM, Schroeder G, Fitzgibbons RJ, Mailliard JA et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998; 16: 2528-2533.
21. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-1118.
22. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18: 243-254.
23. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
24. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896-903.
25. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
26. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
27. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
28. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C et al. Phase in multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
29. Achille E, Tournigand C, André T, Lledo G, Flesch M, Ganem G et al. Folfiri then Folfox, or Folfox then Folfiri in metastatic colorectal cancer (MCRC): results of a phase III trial. Eur J Cancer 2001; 37(Suppl 6): S289 (Abstract).
30. Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M et al. Folfiri followed by Folfox versus Folfox followed by Folfiri in metastatic colorectal cancer (MCRC): final results of a phase III trial. Proc ASCO 2001; abstract 494.
31. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78: 1639-1645.
32. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-258.
33. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987; 5: 1836-1840.
34. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227-235.
35. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 236-244.